<DOC>
	<DOC>NCT01294397</DOC>
	<brief_summary>This is a multi-center, open-label, single sequence, denosumab single-dose study in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis (RA) being treated with etanercept.</brief_summary>
	<brief_title>Effects of Denosumab on the Pharmacokinetics of Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Postmenopausal women (postmenopausal is defined as no vaginal bleeding or spotting for at least 12 months) Low bone mineral density (BMD) as determined by screening BMD Tscores of the lumbar spine (L1 to L4), or total evaluable vertebrae (if fewer than L1 to L4), or total hip ≤ 1.0 Receiving a 50mg dose of etanercept once weekly ≥ 6 months prior to screening and expected to continue etanercept treatment at this dose and frequency through EOS If currently taking methotrexate (MTX), receiving a stable dose (7.5 to 20 mg/week) of MTX ≥ 8 weeks prior to screening Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 400 IU vitamin D daily upon enrollment Type 1 diabetes; OR poorly controlled Type 2 diabetes (hemoglobin A1c (HbA1c) &gt; 8.0% at screening; HbA1c ≤ 8.0% within 6 months of screening is acceptable if supporting laboratory documentation is available) History of heart failure, coronary artery bypass graft, or cardiac arrhythmia; OR history of acute coronary syndrome Comorbid autoimmune disease, demyelinating disease, or hematologic abnormalities History of joint replacement in hand and/or wrist; OR history of fused joint in hand and/or wrist Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; OR active dental or jaw condition that requires oral surgery, or nonhealed dental/oral surgery; OR planned invasive dental procedure(s) during the course of the study Previous exposure to denosumab</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>